Clinical cancer advances 2009: Major research advances in cancer treatment, prevention, and screening -A report from the American Society of Clinical Oncology

Journal of Clinical Oncology

Volumn 27, Issue 35, 2009, Pages 6052-6069

  Petrelli, Nicholas J ^a   Winer, Eric P ^a   Brahmer, Julie ^a   Dubey, Sarita ^a   Smith, Sonali ^a   Thomas, Charles ^a   Vahdat, Linda T ^a   Obel, Jennifer ^a   Vogelzang, Nicholas ^a   Markman, Maurie ^a   Sweetenham, John W ^a   Pfister, David ^a   Kris, Mark G ^a   Schuchter, Lynn M ^a   Sawaya, Raymond ^a   Raghavan, Derek ^a   Ganz, Patricia A ^a   Kramer, Barnett ^a  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFINITOR; ALPHA INTERFERON; BENDAMUSTINE; BEVACIZUMAB; CETUXIMAB; DEGARELIX; ELTROMBOPAG; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; GEFITINIB; IMATINIB; PEMETREXED; PLERIXAFOR; PROSTATE SPECIFIC ANTIGEN; TRASTUZUMAB; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; BONE CANCER; BRAIN CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; CONFERENCE PAPER; DRUG EFFICACY; GLIOBLASTOMA; HEAD AND NECK CANCER; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; LARYNX CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MORTALITY; MULTIPLE MYELOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; ONCOLOGY; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN TARGETING; QUALITY OF LIFE; SOFT TISSUE CANCER; STOMACH CANCER; THROMBOCYTOPENIA; THYROID CANCER; UTERINE CERVIX CANCER; ECONOMICS; EVIDENCE BASED MEDICINE; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE POLICY; MALE; MASS SCREENING; MEDICAL RESEARCH; MEDICAL SOCIETY; NEOPLASM; PRACTICE GUIDELINE; PREDICTION AND FORECASTING; REVIEW; TIME; TREATMENT OUTCOME; UNITED STATES;

BIOMEDICAL RESEARCH; EVIDENCE-BASED MEDICINE; FEMALE; FINANCING, GOVERNMENT; HEALTH POLICY; HUMANS; MALE; MASS SCREENING; MEDICAL ONCOLOGY; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; QUALITY OF HEALTH CARE; QUALITY OF LIFE; RESEARCH SUPPORT AS TOPIC; SOCIETIES, MEDICAL; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 73349121354     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.6171     Document Type: Conference Paper

References (54)

1. Muss HB, Berry DA, Cirrincione CT, et al: Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360:2055-2065, 2009
2. Gilbert FJ, Astley SM, Gillan MG, et al: Single reading with computer-aided detection for screening mammography. N Engl J Med 359:1675-1684, 2008
3. O'Shaughnessy J, Osborne C, Pippen J, et al: Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol 27:18s, 2009 (suppl; abstr 3)
4. Tutt A, Robson M, Garber JE, et al: Phase II trial of the oral PARP inhibitor olaparib in BRCAdeficient advanced breast cancer. J Clin Oncol 27: 18s, 2009 (suppl; abstr CRA501)
5. Van Cutsem E, Kang Y, Chung H, et al: Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 27: 18s, 2009 (suppl; abstr LBA4509)
6. Valle JW, Wasan HS, Palmer DD, et al: Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): Results of a multicentre, randomized phase III trial (the UK ABC-02 trial). J Clin Oncol 27:15s, 2009 (suppl; abstr 4503)
7. Wolmark N, Yothers G, O'Connell MJ, et al: A phase III trial comparing mFolfox6 to mFolfox6 + bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J Clin Oncol 27: 18s, 2009 (suppl; abstr LBA4)
8. Kerr D, Gray R, Quirke R, et al: A quantitative multi-gene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in 4 large studies and results of the independent, prospectively-designed QUASAR validation study. J Clin Oncol 27:15s, 2009 (suppl; abstr 4000)
9. Di Nicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712, 2008
10. Thompson IM, Tangen CM, Paradelo J, et al: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term follow-up of a randomized clinical trial. J Urol 181:956-962, 2009
11. US Food and Drug Administration: FDA approves drug for an advanced form of kidney cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm149550.htm
12. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456, 2008
13. Escudier BJ, Bellmunt J, Negrier S, et al: Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-alpha2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 27:15s, 2009 (suppl; abstr 5020)
14. Rini BI, Halabi S, Rosenberg J, et al: Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206. J Clin Oncol 27:18s, 2009 (suppl; abstr LBA5019)
15. de Bono JS, Scher HI, Montgomery RB, et al: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302-6309, 2008
16. Rustin GJ, van der Burg ME: A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRCOV05/EORTC 55955 trials). J Clin Oncol 27: 18s, 2009 (suppl; abstr 1)
17. Munoz N, Manalastas R Jr, Pitisuttithum P, et al: Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6,11, 16, 18) recombinant vaccine in women aged 24-45 years: A randomised, double-blind trial. Lancet 373:1949-1957, 2009
18. Rebbeck TR, Kauff ND, Domchek SM: Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 101:80-87, 2009
19. Schuster SJ, Neelapu SS, Gause BL, et al: Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. J Clin Oncol 27:18s, 2009 (suppl; abstr 2)
20. O'Connor OA, Pro B, Pinter-Brown L, et al: PROPEL: A multi-center phase 2 open-label study of pralatrexate (PDX) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory peripheral T-cell lymphoma. Presented at the 50th Annual Meeting of the American Society of Hematology, San Francisco, CA, December 8, 2008 (abstr)
21. Friedberg JW, Sharman J, Schaefer-Cutillo J, et al: Fostamatinib disodium (FosD), an oral inhibitor of Syk, is well-tolerated and has significant clinical activity in diffuse large B cell lymphoma (DLBCL) and chronic lymphocytic leukemia (SLL/CLL). Presented at the 50th Annual Meeting of the American Society of Hematology, San Francisco, CA, December 7, 2008 (abstr)
22. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008
23. Agrawal Y, Koch WM, Xiao W, et al: Oral human papillomavirus infection before and after treatment for human papillomavirus 16-positive and human papillomavirus 16-negative head and neck squamous cell carcinoma. Clin Cancer Res 14:7143-7150, 2008
24. Stewart JSW, Cohen EE, Licitra L, et al: Phase III study of gefitinib 250 compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 27:1864-1871, 2009
25. Lefebvre JL, Rolland F, Tesselaar M, et al: Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 101:142-152, 2009
26. Pointreau Y, Garaud P, Chapet S, et al: Randomized trial of induction chemotherapy with cisplatin and 5-flourouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101:498-506, 2009
27. Janot F, de Raucourt D, Benhamou E, et al: Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 26:5518-5523, 2008
28. Belani CP, Brodowicz T, Ciuleanu T, et al: Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 27:18s, 2009 (suppl; abstr CRA8000)
29. Mok TS, Wu YL, Thongprasert S, et al: Ge-fitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
30. Kwak EL, Camidge DR, Clark J, et al: Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol 27:15s, 2009 (suppl; abstr 3509)
31. Linos E, Swetter SM, Cockburn MG, et al: Increasing burden of melanoma in the United States. J Invest Dermatol 129:1666-1674, 2009
32. Schwartzentruber DJ, Lawson D, Richards J, et al: A phase III multi-institutional randomized study of immunization with the gp100:209-217(210M) peptide followed by high dose IL-2 compared with high dose IL-2 alone in patients with metastatic melanoma. J Clin Oncol 27:18s, 2009 (suppl; abstr CRA9011)
33. Flaherty K, Puzanov I, Sosman J, et al: Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 27:15s, 2009 (suppl; abstr 9000)
34. Kreisl TN, Kim L, Moore K, et al: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745, 2009
35. Yu AL, Gilman AL, Ozkaynak MF, et al: A phase III randomized trial of the chimeric anti-GD2 antibody ch14.18 with GM-CSF and IL2 as immunotherapy following dose intensive chemotherapy for high-risk neuroblastoma: Children's Oncology Group (COG) study ANBL0032. J Clin Oncol 27:15s, 2009 (suppl; abstr 10067z)
36. The Cancer Genome Atlas Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068, 2008
37. Reg counts and EGFRvIIIspecific immune responses in GBM. J Clin Oncol 27:15s, 2009 (suppl; abstr 2034)
38. Goss E, Lopez AM, Brown CL, et al: ASCO policy statement: Disparities in cancer care. J Clin Oncol 27:2881-2885, 2009
39. Hayanga AJ, Waljee AK, Kaiser HE, et al: Racial clustering and access to colorectal surgeons, gastroenterologists, and radiation oncologists by Africans Americans and Asian Americans in the United States. Arch Surg 144:532-535, 2009
40. Dawood S, Broglio K, Kau SW, et al: Triple receptor-negative breast cancer: The effect of race on response to primary systemic treatment and survival outcomes. J Clin Oncol 27:220-226, 2008
41. Hershman DL, Unger JM, Barlow WE, et al: Treatment quality and outcomes of African American versus white breast cancer patients: Retrospective analysis of Southwest Oncology Studies S8814/ S8897. J Clin Oncol 27:2157-2162, 2009
42. Kumar K, Brim H, Giardiello F, et al: Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans. Clin Cancer Res 15:1155-1161, 2009
43. Settle K, Posner MR, Schumaker LM, et al: Racial survival disparity in head and neck cancer results from low prevalence of human papilloma virus infection in black oropharyngeal cancer patients. Cancer Prev Res 9:776-781, 2009
44. Smith RA, Cokkinides V, Brawley OW: Cancer screening in the United States, 2009: A review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 59:27-41, 2009
45. Nathan PC, Ness KK, Hudson MM, et al: Cancer screening in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS). J Clin Oncol 27:18s, 2009 (suppl; abstr CRA6501)
46. Ryan JL, Heckler C, Dakhil SR, et al: Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebocontrolled clinical trial of 644 cancer patients. J Clin Oncol 27:15s, 2009 (suppl; abstr 9511)
47. Wright AA, Zhang B, Ray A, et al: Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA 300:1665-1673, 2008
48. Phelps AC, Maciejewski PK, Nilsson M, et al: Religious coping and use of intensive life-prolonging care near death in patients with advanced cancer. JAMA 301:1140-1147, 2009
49. Andriole GL, Crawford ED, Grubb RL 3rd, et al: Mortality results from a randomized prostatecancer screening trial. N Engl J Med 360:1310-1319, 2009
50. Schröder FH, Hugosson J, Roobol MJ, et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328, 2009
51. Kramer BS, Hagerty KL, Justman S, et al: Use of 5-1α-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol 27:1502-1516, 2009
52. Lippman SM, Klein EA, Goodman PJ, et al: Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial. JAMA 301:39-51, 2009
53. Neuhouser ML, Wassertheil-Smoller S, Thomson C, et al: Multivitamin use and risk of cancer and cardiovascular disease in the Women's Health Initiative cohorts. Arch Intern Med 169:294-304, 2009
54. Croswell JM, Kramer BS, Kreimer AR, et al: Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med 7:212-222, 2009